When pharmaceutical companies invent a new drug, they need to originate not ONE name but TWO. They need a trademark name, but they need to create a generic name too, so that copycat manufacturers don't face the problem of "What can I call this without infringing the trademark?" If they don't, they may more easily lose their trademark. Think "nylon", "eversharp pen", "aspirin", "cellophane", and lots more one-time trademarks which became generic. It's a shame that Bob McNally didn't do that in the first place.

Dave Oesterreich